Aadi Bioscience, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Lennon
- Full Time Employees
- 53
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17383 Sunset Boulevard Pacific Palisades CA United States of America 90272
- IPO Date
- Feb 16, 2018
- CIK
- 0001422142
- Website
- aadibio.com
- Similar Companies
- Business
- Aadi Bioscience, Inc. (NASDAQ: AADI) develops and commercializes precision therapies for genetically defined cancers driven by mTOR pathway alterations; its lead product, FYARRO (nab-sirolimus albumin-bound particles for injectable suspension), targets adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), an ultra-rare sarcoma; the company advances nab-sirolimus in clinical trials including the tumor-agnostic PRECISION 1 study for solid tumors harboring TSC1 or TSC2 inactivating alterations. Founded in 2011 as Aadi, LLC and headquartered in Pacific Palisades, California, the firm operates primarily in the United States with a focus on oncology precision medicine leveraging albumin-bound nanoparticle technology to overcome limitations of prior mTOR inhibitors in drug delivery, safety, and targeting. In December 2024, Aadi in-licenses an exclusive global portfolio of three preclinical next-generation antibody-drug conjugates (ADCs) developed via WuXi Biologics and HANGZHOU DAC collaboration, targeting broadly expressed tumor antigens with advanced linker-payload platforms; it concurrently sells FYARRO and associated infrastructure to KAKEN Pharmaceutical for $100 million upfront and secures $100 million in PIPE financing led by Ally Bridge Group with OrbiMed, Invus, and others to fund ADC development into late 2028; in March 2025, KAKEN acquires Aadi Bioscience, marking its transition from a commercial-stage mTOR-focused entity to a preclinical oncology platform emphasizing ADCs.
Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027
Aadi Bioscience (NASDAQ:AADI) versus Nabriva Therapeutics (NASDAQ:NBRV) Head-To-Head Analysis
Reviewing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI)
Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy?
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update